PMC:7105881 / 57336-57601
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T328 | 36-40 | Body_part | denotes | face | http://purl.org/sig/ont/fma/fma24728 |
T329 | 201-208 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T19 | 36-40 | Body_part | denotes | face | http://purl.obolibrary.org/obo/UBERON_0001456 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T663 | 36-40 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | face |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T7910 | 165-174 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
T93211 | 201-208 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T306 | 0-265 | Sentence | denotes | However, these subunit vaccines may face some important challenges, mostly arising from their relatively low immunogenicity, which must be combined with appropriate adjuvants or optimized for suitable protein sequences, fragment lengths, and immunization schedules. |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T956 | 109-123 | BV_15 | denotes | immunogenicity |
T957 | 165-174 | CHEBI:60809;CHEBI:60809 | denotes | adjuvants |
T9588 | 109-123 | BV_15 | denotes | immunogenicity |
T18188 | 165-174 | CHEBI:60809;CHEBI:60809 | denotes | adjuvants |